About: African swine fever vaccines: a promising work still in progress

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: African swine fever vaccines: a promising work still in progress Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	African swine fever vaccines: a promising work still in progress
Creator	Rodriguez, Fernando Bosch-Camós, Laia López, Elisabeth
source	PMC
abstract	ABSTRACT: African swine fever (ASF), a disease of obligatory declaration to the World Organization for Animal Health (OIE), has contributed to poverty and underdevelopment of affected areas. The presence of ASF has been historically neglected in Africa, contributing to its uncontrolled expansion and favouring its spread to continental Europe on at least three occasions, the last one in 2007 through the Republic of Georgia. Since then, African swine fever virus (ASFV) has spread to neighbouring countries, reaching the European Union in 2014, China in the summer of 2018 and spreading through Southeast Asia becoming a global problem. Lack of available vaccines against ASF makes its control even more difficult, representing today the number one threat for the swine industry worldwide and negatively affecting the global commerce equilibrium. MAIN BODY: In this review, we intend to put in perspective the reality of ASF vaccination today, taking into account that investment into ASF vaccine development has been traditionally unattractive, overall since ASF-free areas with large swine industries applied a non-vaccination policy for diseases listed by the OIE. The dramatic situation suffered in Asia and the increasing threat that ASF represents for wealthy countries with large swine industries, has dramatically changed the perspective that both private and public bodies have about ASF vaccinology, although this is controversial. The feasibility of modifying the ASFV genome has led to safe and efficacious experimental recombinant live attenuated viruses (LAVs). The main challenge today will be confirming the safety and efficacy of these technologies in the field, accelerating transfer to the industry for official registration and commercialization. The complexity of ASFV, together with the lack of knowledge about the mechanisms involved in protection and the specific antigens involved in it, requires further investment in research and development. Although far from the efficacy achieved by LAVs, subunit vaccines are the optimal choice for the future. If the world can wait for them or not is a contentious issue. CONCLUSION: Despite their inherent disadvantages, LAVs will be the first technology to reach the market, while subunit vaccines will need much further research to become a successful commercial reality.
has issue date	2020-07-02(xsd:dateTime)
bibo:doi	10.1186/s40813-020-00154-2
has license	cc-by
sha1sum (hex)	e487b14c2635c36c8f5a23e5c30328a75d36d206
schema:url	https://doi.org/10.1186/s40813-020-00154-2
resource representing a document's title	African swine fever vaccines: a promising work still in progress
has PubMed Central identifier	PMC7329361
schema:publication	Porcine Health Manag
resource representing a document's body	covid:e487b14c2635c36c8f5a23e5c30328a75d36d206#body_text
is schema:about of	named entity 'technologies' named entity 'declaration' named entity 'market' named entity 'Lack' named entity 'Conclusion' named entity '2018' named entity 'underdevelopment' named entity 'industry' named entity 'African swine fever' named entity 'SPREAD' named entity 'IS A' named entity 'SUFFERED' named entity 'LACK' named entity 'FEASIBILITY' named entity 'SAFE' named entity 'TRANSFER' named entity 'COMMERCIALIZATION' named entity 'SOUTHEAST ASIA' named entity 'CHINA' named entity 'CONTRIBUTING' named entity 'MARKET' named entity 'AFRICAN SWINE FEVER VIRUS' named entity 'LARGE' named entity 'DISEASES' named entity 'APPLIED' named entity 'WORLDWIDE' named entity 'WAIT' named entity 'HAVE' named entity 'vaccination' named entity 'reach' named entity 'investment' named entity 'policy' named entity 'industry' named entity 'viruses' named entity 'Despite' named entity 'swine fever' named entity 'involved' named entity 'virus' named entity 'efficacy' named entity 'successful' named entity 'involved' named entity 'continental Europe' named entity 'commercial' named entity 'equilibrium' named entity 'poverty' named entity 'represents' named entity 'number' named entity 'private' named entity 'Republic of Georgia' named entity 'ASF' named entity 'ASFV' named entity 'ASF' named entity 'ASF' named entity 'live attenuated' named entity 'global commerce' named entity 'China' named entity 'vaccination' named entity 'African swine fever' named entity 'ASF' named entity 'viruses' named entity 'vaccination policy' named entity 'ASFV' named entity 'ASF' named entity 'vaccines' named entity 'humoral' named entity 'Babraham' named entity 'nonpathogenic' named entity 'virus' named entity 'virus' named entity 'immunization' named entity 'ASFV' named entity 'phylogenetically' named entity 'spreading to other European countries' named entity 'adenovirus' named entity 'recombinant' named entity 'immune complex' named entity 'antigens' named entity 'gene' named entity 'ASFV' named entity 'virulent' named entity 'vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software